Intermune's Canaccord call today is worth a listen for those who mildly follow the company. There is some new stuff re their HCV development (small peaks at future). Its little bits so don't expect too much detail till AASLD.
At AASLD they will present several abstracts related to current and new programs #msg-31432967. Most notably Dan Welch strongly hinted that combination studies in 2 different HCV models with both Roche Polymerases (individually not 3 drug combo) showing promise for human studies (without Peg).
Also, not discussed about but on the slide is InterMune's 2nd generation Protease ITMN-5489 which interestingly is non-macrocyclic (191 is macrocyclic). Also briefly mentioned was InterMune's other HCV target (not partnered) is a class of Helicase Inhibitors.
Market Data 
Markets 
AI
